Effect of intensive insulin therapy on first-phase insulin secretion in newly diagnosed type 2 diabetic patients with a family history of the disease

Li,Qing; Wang,Luan; Xiao,Lin; Wang,Zhongchao; Wang,Fang; Yu,Xiaolong; Yan,Shengli; Wang,Yangang

doi:10.3892/etm.2014.2114

Effect of intensive insulin therapy on first-phase insulin secretion in newly diagnosed type 2 diabetic patients with a family history of the disease

Authors:
- Qing Li
- Luan Wang
- Lin Xiao
- Zhongchao Wang
- Fang Wang
- Xiaolong Yu
- Shengli Yan
- Yangang Wang
View Affiliations

Affiliations: Department of Clinical Laboratory, The First People's Hospital of Zibo City, Zibo, Shandong 255200, P.R. China, Department of Endocrinology, Stem Cell Research Center, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong 266003, P.R. China, Biochemistry Office, Weifang Medical College, Weifang, Shandong 261042, P.R. China
Published online on: December 8, 2014 https://doi.org/10.3892/etm.2014.2114
Pages: 612-618

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Intensive insulin treatment is known to improve β‑cell function in the majority of patients with newly diagnosed type 2 diabetes mellitus (T2DM), and family history (FH) is known to be an important independent risk factor for T2DM. Thus, the aim of the present study was to investigate the difference in first‑phase insulin secretion and the effect of intensive insulin therapy on the improvement of β‑cell function between T2DM patients with and without a FH of diabetes. Patients with newly diagnosed T2DM and healthy controls were divided into groups according to their FH of diabetes. Improvement in β‑cell function was evaluated with an arginine stimulation test after two weeks of continuous subcutaneous insulin infusion (CSII). Compared with the control group, the level of fasting insulin and the homeostasis model assessment of insulin resistance (HOMA2‑IR) were higher in the DM group, while the homeostasis model assessment of β‑cell insulin secretion (HOMA2‑%β) and the first‑phase peak ratio were lower (P<0.05). In addition, the first‑phase peak ratio in the FH‑ control group was higher compared with that in the FH+ control group (P=0.023). Following CSII, all the patients achieved excellent blood glucose control in 6.2±3.6 days, without severe adverse effects. In the DM groups, the fasting insulin level and HOMA2‑IR were lower, while the HOMA2‑%β and first‑phase peak ratio were higher, when compared with the values prior to treatment, particularly in the FH‑ DM group. The HOMA2‑%β in the FH+ DM group was lower compared with the FH‑ DM group (P=0.027). Therefore, T2DM patients with and without a FH of the disease were shown to have a good response to CSII in the improvement of insulin resistance and β‑cell function; however, the improvements were less significant in patients with a FH compared with patients without a FH of diabetes.

View Figures

View References

1	Polonsky KS, Sturis J and Bell GI: Seminars in medicine of the Beth Israel Hospital, Boston. Non-insulin dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 334:777–783. 1996. View Article : Google Scholar : PubMed/NCBI
2	Retnakaran R and Zinman B: Short-term intensified insulin treatment in type 2 diabetes: long-term effects on β-cell function. Diabetes Obes Metab. 14(Suppl 3): 161–166. 2012. View Article : Google Scholar
3	Tian J, Wang J, Li Y, et al: Endothelial function in patients with newly diagnosed type 2 diabetes receiving early intensive insulin therapy. Am J Hypertens. 25:1242–1248. 2012.PubMed/NCBI
4	Harrison LB, Adams-Huet B, Raskin P and Lingvay I: β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 35:1406–1412. 2012. View Article : Google Scholar : PubMed/NCBI
5	Fukui T and Hirano T: High-density lipoprotein subspecies between patients with type 1 diabetes and type 2 diabetes without/with intensive insulin therapy. Endocr J. 59:561–569. 2012. View Article : Google Scholar
6	Chen A, Huang Z, Wan X, et al: Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care. 35:474–481. 2012. View Article : Google Scholar : PubMed/NCBI
7	Fang D, Guan H, Liu J, et al: Early intensive insulin therapy attenuates the p38 pathway in the renal cortex and indices of nephropathy in diabetic rats. Endocr J. 59:81–90. 2012. View Article : Google Scholar
8	Dailey G: Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. Clin Ther. 33:665–678. 2011. View Article : Google Scholar : PubMed/NCBI
9	Holman RR, Paul SK, Bethel MA, Matthews DR and Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 359:1577–1589. 2008. View Article : Google Scholar : PubMed/NCBI
10	Gaede P, Lund-Andersen H, Parving HH and Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 358:580–591. 2008. View Article : Google Scholar : PubMed/NCBI
11	Hu Y, Li L, Xu Y, et al: Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission. Diabetes Care. 34:1848–1853. 2011. View Article : Google Scholar : PubMed/NCBI
12	Shah PK, Mudaliar S, Chang AR, et al: Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metab. 13:505–510. 2011. View Article : Google Scholar : PubMed/NCBI
13	Weng J, Li Y, Xu W, et al: Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 371:1753–1760. 2008. View Article : Google Scholar : PubMed/NCBI
14	Valdez R, Yoon PW, Liu T and Khoury MJ: Family history and prevalence of diabetes in the U.S. population: the 6-year results from the National Health and Nutrition Examination Survey (1999–2004). Diabetes Care. 30:2517–2522. 2007. View Article : Google Scholar : PubMed/NCBI
15	Li P, Zhang JF, Li L, et al: The impact of a family history of type 2 diabetes on insulin secretion and insulin sensitivity in individuals with varying glucose tolerance. Am J Med Sci. 345:22–27. 2013. View Article : Google Scholar
16	Xia Z, Wang Z, Cai Q, et al: Prevalence and risk factors of type 2 diabetes in the adults in Haikou city, Hainan island, China. Iran J Public Health. 42:222–230. 2013.PubMed/NCBI
17	Oh YJ, Nam HK, Rhie YJ, Park SH and Lee KH: Low serum adiponectin levels in Korean children with a family history of type 2 diabetes mellitus. Horm Res Paediatr. 77:382–387. 2012. View Article : Google Scholar : PubMed/NCBI
18	Das M, Pal S and Ghosh A: Family history of type 2 diabetes and prevalence of metabolic syndrome in adult Asian Indians. J Cardiovasc Dis Res. 3:104–108. 2012. View Article : Google Scholar : PubMed/NCBI
19	Lambert M: ADA releases revisions to recommendations for standards of medical care in diabetes. Am Fam Physician. 85:514–515. 2012.PubMed/NCBI
20	Bhowmik B, Diep LM, Munir SB, et al: HbA(1c) as a diagnostic tool for diabetes and pre-diabetes: the Bangladesh experience. Diabet Med. 30:e70–e77. 2013. View Article : Google Scholar
21	Praveen EP, Sahoo J, Khurana ML, et al: Insulin sensitivity and β-cell function in normoglycemic offspring of individuals with type 2 diabetes mellitus: Impact of line of inheritance. Indian J Endocrinol Metab. 16:105–111. 2012. View Article : Google Scholar : PubMed/NCBI
22	Zengi A, Ercan G, Caglayan O, et al: Increased oxidative DNA damage in lean normoglycemic offspring of type 2 diabetic patients. Exp Clin Endocrinol Diabetes. 119:467–471. 2011. View Article : Google Scholar : PubMed/NCBI
23	Retnakaran R, Qi Y, Opsteen C, Vivero E and Zinman B: Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab. 12:909–915. 2010. View Article : Google Scholar : PubMed/NCBI
24	Opsteen C, Qi Y, Zinman B and Retnakaran R: Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. J Eval Clin Pract. 18:256–261. 2012. View Article : Google Scholar
25	Chon S, Oh S, Kim SW, et al: The effect of early insulin therapy on pancreatic β-cell function and long-term glycemic control in newly diagnosed type 2 diabetic patients. Korean J Intern Med. 25:273–281. 2010. View Article : Google Scholar : PubMed/NCBI
26	Li HQ, Wang BP, Deng XL, et al: Insulin improves β-cell function in glucose-intolerant rat models induced by feeding a high-fat diet. Metabolism. 60:1566–1574. 2011. View Article : Google Scholar : PubMed/NCBI Zengi A, Ercan G, Caglayan O, et al: Increased oxidative DNA damage in lean normoglycemic offspring of type 2 diabetic patients. Exp Clin Endocrinol Diabetes. 119:467–471. 2011. View Article : Google Scholar : PubMed/NCBI